MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- CIPLA - MYLAN (US)
CIPLA vs MYLAN (US) - Comparison Results
CIPLA Change
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 CIPLA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CIPLA Mar-20 |
MYLAN Dec-18 |
CIPLA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 586 | 3,443 | - | |
| Low | Rs | 357 | 1,895 | - | |
| Sales per share (Unadj.) | Rs | 207.0 | 1,584.4 | - | |
| Earnings per share (Unadj.) | Rs | 18.6 | 43.0 | - | |
| Cash flow per share (Unadj.) | Rs | 33.2 | 339.7 | - | |
| Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 195.5 | 1,714.1 | - | |
| Shares outstanding (eoy) | m | 806.35 | 514.50 | - | |
| Bonus/Rights/Conversions | ESOS | - | - | ||
| Price / Sales ratio | x | 2.3 | 1.7 | 135.1% | |
| Avg P/E ratio | x | 25.3 | 62.0 | 40.8% | |
| P/CF ratio (eoy) | x | 14.2 | 7.9 | 180.8% | |
| Price / Book Value ratio | x | 2.4 | 1.6 | 154.8% | |
| Dividend payout | % | 21.5 | 0 | - | |
| Avg Mkt Cap | Rs m | 379,912 | 1,373,379 | 27.7% | |
| No. of employees | `000 | 25.8 | 35.0 | 73.8% | |
| Total wages/salary | Rs m | 30,270 | 0 | - | |
| Avg. sales/employee | Rs Th | 6,459.6 | 23,291.4 | 27.7% | |
| Avg. wages/employee | Rs Th | 1,171.2 | 0 | - | |
| Avg. net profit/employee | Rs Th | 580.2 | 632.5 | 91.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 166,949 | 815,199 | 20.5% | |
| Other income | Rs m | 3,442 | 0 | - | |
| Total revenues | Rs m | 170,391 | 815,199 | 20.9% | |
| Gross profit | Rs m | 32,060 | 210,943 | 15.2% | |
| Depreciation | Rs m | 11,747 | 152,637 | 7.7% | |
| Interest | Rs m | 1,974 | 39,208 | 5.0% | |
| Profit before tax | Rs m | 21,782 | 19,098 | 114.1% | |
| Minority Interest | Rs m | -475 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 6,312 | -3,038 | -207.7% | |
| Profit after tax | Rs m | 14,995 | 22,136 | 67.7% | |
| Gross profit margin | % | 19.2 | 25.9 | 74.2% | |
| Effective tax rate | % | 29.0 | -15.9 | -182.1% | |
| Net profit margin | % | 9.0 | 2.7 | 330.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 117,038 | 455,207 | 25.7% | |
| Current liabilities | Rs m | 43,931 | 331,896 | 13.2% | |
| Net working cap to sales | % | 43.8 | 15.1 | 289.5% | |
| Current ratio | x | 2.7 | 1.4 | 194.2% | |
| Inventory Days | Days | 96 | 84 | 114.5% | |
| Debtors Days | Days | 85 | 93 | 91.2% | |
| Net fixed assets | Rs m | 107,424 | 158,135 | 67.9% | |
| Share capital | Rs m | 1,613 | 434 | 371.5% | |
| Net worth | Rs m | 157,630 | 881,897 | 17.9% | |
| Long term debt | Rs m | 23,693 | 951,850 | 2.5% | |
| Total assets | Rs m | 236,626 | 2,365,590 | 10.0% | |
| Interest coverage | x | 12.0 | 1.5 | 809.4% | |
| Debt to equity ratio | x | 0.2 | 1.1 | 13.9% | |
| Sales to assets ratio | x | 0.7 | 0.3 | 204.7% | |
| Return on assets | % | 7.2 | 2.6 | 276.5% | |
| Return on equity | % | 9.5 | 2.5 | 379.0% | |
| Return on capital | % | 12.8 | 3.2 | 403.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 30,685 | 169,399 | 18.1% | |
| From Investments | Rs m | 1,040 | -87,560 | -1.2% | |
| From Financial Activity | Rs m | -29,488 | -78,916 | 37.4% | |
| Net Cashflow | Rs m | 2,340 | 1,403 | 166.8% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 72.34 Rs / USD
Compare CIPLA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare CIPLA With: FRESENIUS KABI ONCO. AJANTA PHARMA SUVEN LIFE SCIENCES AUROBINDO PHARMA FULFORD INDIA
Today's Market
Sensex Zooms 1,030 Points, Nifty Tops 14,980-Mark; HDFC Bank Among Top Gainers(Closing)
Indian share markets witnessed huge buying interest during the extended closing hours today and ended their day on a strong note.
Related Views On News
CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)
Feb 1, 2021 | Updated on Feb 1, 2021For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA 2019-20 Annual Report Analysis (Annual Result Update)
Nov 4, 2020 | Updated on Nov 4, 2020Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 9, 2019 | Updated on Sep 9, 2019Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
More Views on NewsMost Popular
Intraday Trading for a Living (Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Penny Stock Master Series: The Quest for 10X Profits in 10 Years (Profit Hunter)
Feb 12, 2021This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)
Feb 16, 2021Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More
